Form 4: Travere Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher R. Cline, CFO of Travere Therapeutics, sold 514 shares of common stock to cover tax withholding obligations related to vested restricted stock units.
Summary
- On September 4, 2024, Christopher R. Cline, the Chief Financial Officer of Travere Therapeutics, Inc., sold 514 shares of the company's common stock.
- The sale was executed at a price of $9.5093 per share.
- The transaction was conducted to cover the tax withholding obligation associated with the settlement of vested restricted stock units.
- Following the transaction, Cline directly owns 70,335 shares of Travere Therapeutics stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate positive or negative sentiment about the company's performance.
Future Outlook
The document does not contain any forward-looking statements or guidance.
Industry Context
This is a routine Form 4 filing related to an executive's stock transactions. Such filings are common and provide transparency into the trading activities of company insiders. It is a normal part of equity compensation plans.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of the transaction (sale of shares). |
| 09/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.